Jacobson, Kenneth (NIDDK)
- In vitro data available
This molecular probe may serve as a companion tool to identify and stratify patient populations based on the prevalence of the target A3 adenosine receptors.
Small molecule drugs, A3AR-selective agonists, are currently in advanced clinical trials for the treatment of hepatocellular carcinoma, autoimmune inflammatory diseases, such as rheumatoid arthritis, psoriasis, and dry eye disease, and other conditions.
- Tools to study prevalence of this receptor on neutrophils, a predictor of response to agonist drugs.
- Avoids the use of radioisotopes in this part of the R&D process.